Anemia, Cervical Cancer
Conditions
Keywords
anemia, stage IIB cervical cancer, stage III cervical cancer, stage IVA cervical cancer, cervical adenosquamous cell carcinoma, cervical squamous cell carcinoma, cervical adenocarcinoma
Brief summary
RATIONALE: Epoetin beta may stimulate red blood cell production to prevent or control anemia in patients treated with chemotherapy and radiation therapy. PURPOSE: Randomized phase IV trial to determine the effectiveness of epoetin beta in treating anemia in patients who are receiving cisplatin and radiation therapy for stage IIB, stage III, or stage IVA cervical cancer.
Detailed description
OBJECTIVES: * Compare the effectiveness of epoetin beta vs standard care for anemia management, in terms of increased hemoglobin levels and the correlation with reduced relapse/treatment failure rate, in patients with stage IIB, III, or IVA cervical cancer treated with cisplatin and radiotherapy. * Compare the safety of these regimens in these patients. * Compare the relapse-free and overall survival of patients treated with these regimens. * Compare the frequency and localization of relapses and metastases in patients treated with these regimens. * Compare the quality of life of patients treated with these regimens. * Compare the type, frequency, and degree of adverse events in patients treated with these regimens. * Compare the overall response rate in patients treated with these regimens. OUTLINE: This is a randomized, open-label, parallel-group, multicenter study. Patients are stratified according to country, disease stage, and brachytherapy technique. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo radiotherapy 5 days a week for 6 weeks. Patients also undergo high-dose rate, low-dose rate, or boost brachytherapy. Patients receive cisplatin IV beginning on day 1 of radiotherapy and continuing weekly for 6 weeks. Patients also receive epoetin beta subcutaneously 3 times a week beginning 2 weeks before radiotherapy and continuing for 8 weeks. * Arm II: Patients undergo radiotherapy and brachytherapy and receive cisplatin as in arm I. Quality of life is assessed at baseline, after the last treatment, and at 3 months. Patients are followed every 3 months for 2 years and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 80-450 patients will be accrued for this study within 4-22.5 months.
Interventions
BIOLOGICALepoetin beta
DRUGcisplatin
RADIATIONbrachytherapy
RADIATIONradiation therapy
Sponsors
AGO Study Group
Study design
Allocation
RANDOMIZED
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed stage IIB, III, or IVA cervical cancer * No chorion carcinoma or neuroendocrine small cell carcinoma * Previously untreated disease * Must be scheduled to undergo radiotherapy and receive cisplatin as primary therapy * Hemoglobin 8.0-13.0 g/dL * No relevant acute bleeding within the past 3 months, including anemia caused by gross bleeding from tumor * No distant metastasis * No positive para-aortic lymph nodes PATIENT CHARACTERISTICS: Age * Over 18 Performance status * WHO 0-2 Life expectancy * At least 3 months Hematopoietic * See Disease Characteristics * WBC greater than 3,000/mm3 * Platelet count greater than 100,000/mm3 * No hemolytic anemia * No transferrin saturation less than 20% that cannot be treated with IV iron * No hemoglobinopathies (i.e., sickle cell disease or thalassemia of all types) Hepatic * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * Transaminases no greater than 2.5 times ULN * Alkaline phosphatase no greater than 2.5 times ULN Renal * Creatinine clearance greater than 60 mL/min Cardiovascular * No chronic heart failure * No New York Heart Association class II-IV heart disease * No uncontrolled arterial hypertension (systolic blood pressure at least 170 mmHg, diastolic blood pressure at least 100 mmHg) * No prior deep vein thrombosis * No thrombocytosis Other * No vitamin B12 deficiency * No folic acid deficiency * No newly diagnosed (unstable) epilepsy * No acute infection * No other malignancy within the past 5 years except basal cell carcinoma in situ * No known peripheral neuropathy or moto-sensory neurotoxicity grade 2 or greater * No impaired hearing grade 2 or greater * No hypersensitivity to benzyl alcohol, benzoic acid, benzalkonium chloride, or any excipients of cisplatin preparations * Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy * At least 3 months since prior epoetins or related compounds Chemotherapy * See Disease Characteristics Endocrine therapy * Not specified Radiotherapy * See Disease Characteristics * No prior radiotherapy for cervical cancer Surgery * Not specified Other * At least 30 days since prior investigational drugs * No prior systemic antineoplastic therapy for cervical cancer * No other concurrent investigational drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of treatment failures within 6 months after beginning radiochemotherapy (RCT) (stage I) | — |
| Overall survival after RCT (stage II) | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival after RCT (stage I) | — |
| Frequency and localization of relapses and/or metastases | — |
| Change in hemoglobin from baseline during therapy | — |
| Quality of life as assessed by the Functional Assessment of Cancer Therapy-Anemia | — |
| Progression/relapse-free survival | — |
| Safety | — |
| Vital signs | — |
| Number of treatment failures within 6 months after beginning RCT (stage II) | — |
| Type, frequency, and degree of adverse events | — |
| Overall response rate to RCT | — |
Countries
Germany
Outcome results
None listed